Parkinsonism in patients with a history of amphetamine exposure
Identifieur interne : 000346 ( Istex/Corpus ); précédent : 000345; suivant : 000347Parkinsonism in patients with a history of amphetamine exposure
Auteurs : Chadwick W. Christine ; Elisabeth R. Garwood ; Lauren E. Schrock ; Daniel E. Austin ; Charles E. MccullochSource :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
English descriptors
- KwdEn :
Abstract
We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22915
Links to Exploration step
ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California</mods:affiliation></affiliation></author><author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name><affiliation><mods:affiliation>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name><affiliation><mods:affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah</mods:affiliation></affiliation></author><author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name><affiliation><mods:affiliation>Colby College, Waterville, Maine</mods:affiliation></affiliation></author><author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name><affiliation><mods:affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22915</idno><idno type="url">https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000346</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title><author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name><affiliation><mods:affiliation>Department of Neurology, University of California, San Francisco, California</mods:affiliation></affiliation></author><author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name><affiliation><mods:affiliation>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name><affiliation><mods:affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah</mods:affiliation></affiliation></author><author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name><affiliation><mods:affiliation>Colby College, Waterville, Maine</mods:affiliation></affiliation></author><author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name><affiliation><mods:affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30">2010-01-30</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="231">231</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</idno><idno type="DOI">10.1002/mds.22915</idno><idno type="ArticleID">MDS22915</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>neurotoxicant</term><term>neurotoxin</term><term>selective vulnerability</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Chadwick W. Christine MD</name><affiliations><json:string>Department of Neurology, University of California, San Francisco, California</json:string></affiliations></json:item><json:item><name>Elisabeth R. Garwood BS</name><affiliations><json:string>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</json:string></affiliations></json:item><json:item><name>Lauren E. Schrock MD</name><affiliations><json:string>Department of Neurology, University of Utah, Salt Lake City, Utah</json:string></affiliations></json:item><json:item><name>Daniel E. Austin</name><affiliations><json:string>Colby College, Waterville, Maine</json:string></affiliations></json:item><json:item><name>Charles E. McCulloch PhD</name><affiliations><json:string>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>neurotoxin</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>selective vulnerability</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neurotoxicant</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P > 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>7.712</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1502</abstractCharCount><pdfWordCount>12171</pdfWordCount><pdfCharCount>80524</pdfCharCount><pdfPageCount>22</pdfPageCount><abstractWordCount>226</abstractWordCount></qualityIndicators><title>Parkinsonism in patients with a history of amphetamine exposure</title><genre><json:string>Serial article</json:string></genre><host><volume>25</volume><pages><total>4</total><last>231</last><first>228</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22915</json:string></doi><id>13231344BAE719D1985262921EA0739AE1D6AF96</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2010</date></publicationStmt><notesStmt><note>UCSF Department of Neurology</note><note>Genzyme</note><note>University of California</note><note>Doris Duke Charitable Foundation</note><note>San Francisco VA PADREC</note><note>NIH</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title><author><persName><forename type="first">Chadwick W.</forename><surname>Christine</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Department of Neurology, UCSF, 400 Parnassus Avenue, Box 0348, San Francisco, CA 94143</p></note><affiliation>Department of Neurology, University of California, San Francisco, California</affiliation></author><author><persName><forename type="first">Elisabeth R.</forename><surname>Garwood</surname><roleName type="degree">BS</roleName></persName><affiliation>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</affiliation></author><author><persName><forename type="first">Lauren E.</forename><surname>Schrock</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah</affiliation></author><author><persName><forename type="first">Daniel E.</forename><surname>Austin</surname></persName><affiliation>Colby College, Waterville, Maine</affiliation></author><author><persName><forename type="first">Charles E.</forename><surname>McCulloch</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30"></date><biblScope unit="vol">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="228">228</biblScope><biblScope unit="page" to="231">231</biblScope></imprint></monogr><idno type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</idno><idno type="DOI">10.1002/mds.22915</idno><idno type="ArticleID">MDS22915</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>neurotoxin</term></item><item><term>selective vulnerability</term></item><item><term>neurotoxicant</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-04-22">Received</change><change when="2009-10-30">Registration</change><change when="2010-01-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v25:2</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2010-01-30">30 January 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22915</doi><idGroup><id type="unit" value="MDS22915"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-04-22"></event><event type="manuscriptRevised" date="2009-09-19"></event><event type="manuscriptAccepted" date="2009-10-30"></event><event type="firstOnline" date="2010-01-08"></event><event type="publishedOnlineFinalForm" date="2010-02-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-01-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-19"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">228</numbering><numbering type="pageLast">231</numbering></numberingGroup><correspondenceTo>Department of Neurology, UCSF, 400 Parnassus Avenue, Box 0348, San Francisco, CA 94143</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22915.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="16"></count><count type="wordTotal" number="2690"></count></countGroup><titleGroup><title type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title><title type="short" xml:lang="en">Parkinsonism with Amphetamine Exposure</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Chadwick W.</givenNames><familyName>Christine</familyName><degrees>MD</degrees></personName><contactDetails><email>chad.christine@ucsf.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Elisabeth R.</givenNames><familyName>Garwood</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Lauren E.</givenNames><familyName>Schrock</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Daniel E.</givenNames><familyName>Austin</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Charles E.</givenNames><familyName>McCulloch</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of California, San Francisco, California</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Utah, Salt Lake City, Utah</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Colby College, Waterville, Maine</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="US" type="organization"><unparsedAffiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">neurotoxin</keyword><keyword xml:id="kwd2">selective vulnerability</keyword><keyword xml:id="kwd3">neurotoxicant</keyword></keywordGroup><fundingInfo><fundingAgency>UCSF Department of Neurology</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Genzyme</fundingAgency></fundingInfo><fundingInfo><fundingAgency>University of California</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Doris Duke Charitable Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>San Francisco VA PADREC</fundingAgency></fundingInfo><fundingInfo><fundingAgency>NIH</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; <i>P</i> < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1" numbered="no"><p>Potential conflict of interest: Nothing to report.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Parkinsonism in patients with a history of amphetamine exposure</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Parkinsonism with Amphetamine Exposure</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Parkinsonism in patients with a history of amphetamine exposure</title></titleInfo><name type="personal"><namePart type="given">Chadwick W.</namePart><namePart type="family">Christine</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of California, San Francisco, California</affiliation><description>Correspondence: Department of Neurology, UCSF, 400 Parnassus Avenue, Box 0348, San Francisco, CA 94143</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elisabeth R.</namePart><namePart type="family">Garwood</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Pennsylvania State University College of Medicine, Hershey, Pennsylvania</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lauren E.</namePart><namePart type="family">Schrock</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Utah, Salt Lake City, Utah</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel E.</namePart><namePart type="family">Austin</namePart><affiliation>Colby College, Waterville, Maine</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Charles E.</namePart><namePart type="family">McCulloch</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Epidemiology and Biostatistics, University of California, San Francisco, California</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-01-30</dateIssued><dateCaptured encoding="w3cdtf">2009-04-22</dateCaptured><dateValid encoding="w3cdtf">2009-10-30</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">1</extent><extent unit="references">16</extent><extent unit="words">2690</extent></physicalDescription><abstract lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</abstract><note type="funding">UCSF Department of Neurology</note><note type="funding">Genzyme</note><note type="funding">University of California</note><note type="funding">Doris Duke Charitable Foundation</note><note type="funding">San Francisco VA PADREC</note><note type="funding">NIH</note><subject lang="en"><genre>Keywords</genre><topic>neurotoxin</topic><topic>selective vulnerability</topic><topic>neurotoxicant</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>228</start><end>231</end><total>4</total></extent></part></relatedItem><identifier type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</identifier><identifier type="DOI">10.1002/mds.22915</identifier><identifier type="ArticleID">MDS22915</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000346 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000346 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96
|texte= Parkinsonism in patients with a history of amphetamine exposure
}}
| This area was generated with Dilib version V0.6.23. |  |